Vertex Pharmaceuticals Inc
Most Recent
How Vertex’s Revenue and Earnings Surprised in 2Q16
Vertex Pharmaceuticals (VRTX) reported its 2Q16 earnings on July 27, 2016. VRTX surpassed Wall Street analysts’ projections and reported revenue of $431.6 million.
What to Expect from BioMarin Pharmaceuticals in 2017
In 2016, BioMarin Pharmaceuticals (BMRN) reported revenues of around $1.1 billion, a ~25% increase year-over-year (or YoY).
How BioMarin Pharmaceutical Is Positioned Financially in August
In the second quarter, BioMarin Pharmaceutical (BMRN) reported revenues of $372.8 million compared to $317.4 million in Q2 2017.
A Look at Incyte’s Valuation as of May 25
Incyte reported EPS of -$0.19 on revenue of $382.3 million in Q1 2018 compared to revenue of $384.1 million in Q1 2017.
How Vertex Pharmaceuticals’ Drugs Performed in 1Q18
In 1Q18, Vertex Pharmaceuticals’ (VRTX) Orkambi revenue rose ~20% YoY (year-over-year) to $354 million from $295 million.
Amgen Rises by 2% as XBI’s Large-Cap Stocks Rally
Amgen closed at $157.60 and was trading above its 50- and 100-day moving averages. The stock also witnessed a rise in trading volumes.
Alnylam Pharmaceuticals: Developing Therapies for Hereditary ATTR Amyloidosis
Alnylam Pharmaceuticals (ALNY) is currently developing three investigational therapies—Patisiran, Revusiran, and ALN-TTRsc02—for the treatment of patients with hereditary ATTR amyloidosis.
Buy Allows Horizon to Further Expand into Orphan Drug Space
Through the acquisition of Raptor Pharmaceuticals, Horizon Pharma (HZNP) will gain access to Procysbi and Quinsair and expand in the orphan drug space.
How Much Does Biogen Spend on Research and Development?
Biogen’s (BIIB) R&D expenses for 4Q15 were $542 million, or 19% of its total revenue, including a $60 million payment to Mitsubishi Tanabe.
Why Are Most Analysts Recommending a ‘Buy’ for Vertex?
On February 16, 2016, after Vertex’s (VRTX) 4Q15 and fiscal 2015 earnings release, revised ratings showed that 76% of analysts now recommend a “buy” for Vertex stock.
Why Is Vertex Pharmaceuticals’ Valuation at a Discount?
On February 17, 2016, Vertex Pharmaceuticals (VRTX) was trading at a forward PE multiple of 15.20x. It’s trading at a discount when compared to peers Alexion (ALXN) and Regeneron (REGN).
How Did Tesla Become Renaissance Technologies’ Gem?
In the fourth quarter of 2019, Tesla was Renaissance Technologies’ second-largest holding. Renaissance is one of the largest hedge funds in the US.
Why CRISPR Therapeutics Stock Rose ~13.05% Yesterday
On January 7, CRISPR Therapeutics stock rose ~13.05% to $34.22 from its previous close of $30.27 on January 4.
A Look at Sarepta Therapeutics’ Recent Developments
In the first nine months of 2018, Sarepta Therapeutics’ (SRPT) net income and EPS amounted to -$221.0 million and -$3.38, respectively, compared to -$26.7 million and -$0.47 in the same period the prior year.
How Is Sarepta Therapeutics Positioned in January?
In the first nine months of 2018, Sarepta Therapeutics’ net revenues grew ~123% YoY to reach $216.6 million from $97.3 million.
Understanding Sarepta Therapeutics’ Operational Performance
Sarepta Therapeutics’ (SRPT) R&D (research and development) expenses rose YoY (year-over-year) to $86.58 million.
Do Analysts See Any Upside for Vertex Stock?
Of the 25 analysts covering Vertex Pharmaceuticals (VRTX), 21 recommend “buy” or a higher rating, and four recommend “hold.”
Vertex Pharmaceuticals’ Gross Margin Trends
Kalydeco, Orkambi, and Symdeko are Vertex Pharmaceuticals’ (VRTX) products on the market.
Do Analysts See Any Upside for bluebird bio Stock?
In this year’s third quarter, bluebird bio (BLUE) generated net interest income of $4.59 million.
Understanding bluebird bio’s Operational Performance
In 2018 and 2019, bluebird bio (BLUE) is expected to generate revenues of $43.62 million and $67.0 million, respectively.
Taking Stock of bluebird bio’s Performance
In the third quarter, bluebird bio’s total revenue rose YoY (year-over-year) to $11.53 million from $7.71 million.
How BioMarin Pharmaceutical’s Financials Look in November
BioMarin Pharmaceutical’s (BMRN) net revenues over the first nine months of this year amounted to $1.1 billion compared to $955.3 million in the same period the prior year.
Biogen Surpassed Estimates in Q3 2018, Reports Strong Growth
Today, Biogen (BIIB) reported EPS of $7.40 on revenues of ~$3.44 billion. BIIB beat the EPS estimate of $6.78 on revenues of ~$3.33 billion.
How Is Vertex Pharmaceuticals Positioned in October?
Vertex announced on October 10 that the FDA has lifted the clinical hold and accepted its Investigational New Drug Application for CTX001.
Analysts Are Mostly Positive on Neurocrine Biosciences
On October 4, Neurocrine Biosciences (NBIX) stock closed at $114.58, which is an ~3.79% decline from its October 3 close of $119.09.
Ionis Pharmaceuticals’ Revenue Growth Rate
Ionis Pharmaceuticals (IONS) reported revenues of $262.0 million during the first half of 2018.
Vertex Pharmaceuticals Strengthens in the Cystic Fibrosis Space
Vertex Pharmaceuticals (VRTX) develops medicines for life-threatening diseases and is presently focused on developing drugs for cystic fibrosis and sickle-cell disease, partnering with CRISPR Therapeutics (CRSP) for the latter.
Estimates and Recommendations for Bluebird Bio on September 6
Wall Street analysts estimate that Bluebird Bio (BLUE) will report a 14.6% growth in revenues to ~$40.6 million in 2018 compared to $35.4 million in 2017.
Bluebird Bio’s Valuation on September 6
Bluebird Bio (BLUE) reported a net loss of $2.91 per share on revenues of $7.8 million in Q2 2018, a 53% decline year-over-year.
How Analysts View BioMarin Pharmaceutical in August
On August 30, 2018, BioMarin Pharmaceutical (BMRN) stock closed at $99.26 which is 7% below its 52-week high of $106.20 on August 2.
An Overview of Roche’s Immunology Drugs Pulmozyme and CellCept
Roche’s CellCept generated revenues of 333.0 million Swiss francs in H1 2018 compared to 346.0 million Swiss francs in H1 2017.
A Look at Incyte’s Valuation on August 22
On August 22, Incyte was trading at a forward price-to-earnings multiple of 38.1x compared to the industry average of ~13.9x.
Analysts Are Bullish on Sarepta Therapeutics
Sarepta Therapeutics (SRPT) reported revenues of $64.6 million and a net loss of $0.55 per share in Q1 2018.
How Does BioMarin Pharmaceutical Look ahead of Its Q2 Earnings?
BioMarin Pharmaceutical (BMRN) plans to release its Q2 2018 results on August 2. In Q1 2018, BMRN reported net revenues of $373.4 million.
Incyte’s Valuations on July 6
Incyte (INCY) posted revenues of $382.3 million in Q1 2018, a marginal decrease in YoY revenues compared to $384.1 million in Q1 2017.
How Ionis Pharmaceuticals’ Valuation Compares
Ionis Pharmaceuticals (IONS), a therapeutics development leader, commercializes products in collaboration with other pharmaceutical companies.
What Led to MEI Pharma Stock’s 55% Rise Last Week?
MEI Pharma (MEIP) saw a 55% rise in its stock price between May 11 and May 18.
CRISPR Stock Has Seen Soild Growth in the Last 12 Months
CRISPR Therapeutics has risen 24% between May 11 and May 17.
Why Regeneron Pharmaceuticals’ Stock Price Fell
Of the 27 analysts tracking Regeneron Pharmaceuticals (REGN) in March, five recommended a “strong buy” and six analysts recommended a “buy.”
Alexion Pharmaceuticals in 4Q17 and Fiscal 2017
In 4Q17, Alexion Pharmaceuticals (ALXN) generated revenues of $910 million, which reflected ~10% growth on a YoY (year-over-year) basis.
Inside Pfizer’s Rare Disease Segment Performance in 2017
In 4Q17, Pfizer’s BeneFix reported revenues of $150 million, which represents a ~11% decline YoY and a ~1% decline quarter-over-quarter.
Vertex Pharmaceuticals to Target 90% of Cystic Fibrosis Patients
Vertex Pharmaceuticals (VRTX) is currently involved in evaluating four triple combination regimens comprised of tezacaftor, ivacaftor, and one of the next-generation correctors.
Vertex Pharmaceuticals Has Robust Late-Stage Research Pipeline
On January 10, 2018, Vertex Pharmaceuticals announced that Orkambi has secured regulatory approval from the European Commission to treat CF patients ages six to 11 years.
A Look at Ionis’s 3Q17 Revenue Stream
Ionis Pharmaceuticals (IONS) reported a 9% rise in its revenue to $120.9 million in 3Q17 compared to $110.9 million in 3Q16.
Analysts’ Recommendations for Bioverativ in January 2018
Fourteen analysts were tracking Bioverativ in January 2018. Four analysts recommended “strong buys,” while two recommended “buys” on the stock.
How’s Incyte’s Valuation in January 2018?
Analysts expect Incyte Corporation’s revenue to rise ~26.7% to $413.8 million in 4Q17 compared to $326.5 million in 4Q16.
Analysts’ Recommendations for Regeneron in September 2017
Of the 26 analysts covering Regeneron Pharmaceuticals in September 2017, seven rated the stock a “strong buy,” six rated it as a “buy,” and 12 rated it as a “hold.” One analyst rated the company as a “strong sell.”
How Is Jazz’s Defitelio Positioned after 2Q17?
In 2Q17, Jazz Pharmaceuticals’ (JAZZ) Defitelio generated revenues of ~$30 million, which represents a ~10% fall YoY and a ~17% fall QoQ.
Behind Bioverativ’s Analyst Recommendations This September
Of the 12 analysts tracking Bioverativ (BIVV), three recommend a “strong buy” for the stock, while one recommends a “buy,” and seven recommend a “hold.”
How Are Orkambi and Kalydeco Positioned after 2Q17?
In 2Q17, Vertex Pharmaceuticals’ (VRTX) Orkambi generated revenues of around $324 million, which reflected a whopping ~32% growth on a year-over-year (or YoY) basis and ~10% growth on a quarter-over-quarter basis.
Alprolix and Eloctate Increasingly Used for Prophylaxis in 2017
Since demand from the target population for prophylaxis is rising rapidly, Bioverativ’s Alprolix and Eloctate are expected to see solid demand trends in 2017.
Bioverativ Expected to Report Healthy Profit Margins in 2017
Bioverativ (BIVV) expects its 2017 GAAP and non-GAAP operating margins to fall 38.0%–42.0% and 43.0%–47.0%, respectively.
Bioverativ Expected to Report Robust Revenue Growth in 2017
In 1Q17, Bioverativ reported revenues close to $259.0 million, driven by its focus on a commercial strategy for its hemophilia products and optimal cost management.
Bioverativ–True North Therapeutics: Stronger Research Pipeline
The acquisition of True North Therapeutics has paved the way for Bioverativ’s (BIVV) entry into cold agglutinin disease (or CAD).
Vertex Pharmaceuticals’ Focus on Innovative Combination Regimens
On March 28, 2017, Vertex Pharmaceutical (VRTX) released data from a phase 3 trial, EVOLVE.
Vertex Pharmaceuticals Cystic Fibrosis Market Could Expand
Vertex Pharmaceuticals’ (VRTX) drugs, Orkambi (lumacaftor/ivacaftor) and Kalydeco (ivacaftor), are capable of treating around 30,000 cystic fibrosis (or CF) patients.
What Drove Biogen Stock in 2Q17?
Biogen (BIIB) stock has risen ~0.40% in 2Q17 and ~4.1% year-to-date as of July 7, 2017.
Inside Vertex Pharmaceuticals’ Clinical Pipeline
In March 2017, Vertex Pharmaceuticals (VRTX) announced promising results from two phase-3 clinical trials, Evolve and Expand.
Inside Vertex Pharmaceuticals’ Revenue Trend
In 2016, Vertex Pharmaceuticals (VRTX) reported revenues of around ~$1.7 billion, which reflected a whopping 65% YoY (year-over-year) growth.
How Incyte’s Valuation Has Changed since 1Q17 Results
Incyte reported revenues of $384.1 million in 1Q17 as compared to $263.5 million in 1Q16.
ALXN1210 Is Expected to Boost Alexion Pharmaceuticals’ Revenue
Alexion Pharmaceuticals has planned five clinical trials in 2017 to test the potential of investigational next-generation C5 antibody, ALXN1210, as a treatment option for complement-mediated diseases.
Biogen’s Targeted Marketing Strategy for Spinraza in 1Q17
To promote the use of Spinraza for SMA, Biogen (BIIB) has been actively educating and creating awareness for the drug among physician and patient communities.
Failed Healthcare Bill Will Impact the Pharmaceutical Industry
Due to the failure of the new healthcare bill, major pharmaceutical companies witnessed a fall in their share prices from March 23, 2017, to March 27, 2017.
Alnylam Pharmaceuticals’s Therapies to Treat hATTR Amyloidosis
The European Medicines Agency (or EMA) has approved tafamidis for stage 1 hATTR amyloidosis.
Vertex Has Adopted Multiple Approaches to Treat Cystic Fibrosis
Vertex Pharmaceuticals (VRTX) is aiming to increase the number of patients eligible to be treated with its drugs to include the entire CF patient population.
Why United Therapeutics Expects Strong Revenue Growth
United Therapeutics (UTHR) expects to earn revenue exceeding $1.5 billion in 2016. By 2020, the company also expects to surpass its goal of $2 billion in annual revenue.
Why Neurocrine Biosciences May See Higher Losses in 2016
Wall Street analysts have projected that Neurocrine Biosciences’ net income in 2016 will be -$146.2 million, a significantly higher loss than in 2015.
Why Europe Is an Important Market for Vertex’s Orkambi
Although there are 12,000 eligible patients in Europe who are 12 years and older, Orkambi hasn’t yet received reimbursement approvals for these patients.
Higher Discontinuations Are among Orkambi’s Concerns
Despite a slower launch of the drug in Germany, Orkambi is expected to generate $1 billion–$1.1 billion in 2016.
How Significant Is Alexion’s Opportunity with Soliris?
Alexion (ALXN) has been serving the atypical hemolytic uremic syndrome, or aHUS, market for the past five years.
Why Has the JPMorgan Large-Cap Growth Fund Done so Poorly in 2016?
The JPMorgan Large-Cap Growth Fund Class A (OLGAX) has dived by 3.9% YTD in 2016. This decline makes it the worst performer among our 12 funds.
ALNY Reports Positive Results from Patisiran’s Open Label Extension Study
On July 1, 2016, Alnylam Pharmaceuticals (ALNY) published positive preliminary results from its ongoing Phase 2 open label extension study.
How Does Vertex Plan to Expand Beyond Cystic Fibrosis?
Vertex is trying to expand its product base beyond cystic fibrosis. It holds molecules in the oncology, respiratory, pain, spinal cord, and influenza spaces.
Consumer Discretionary Drove Down OLGAX’s Returns in 1Q16
OLGAX fell 6.4% in 1Q16. OLGAX fell 3.7% in the one-year period ended March 2016 and ranked ninth among its peer group.
Ionis Pharmaceuticals: Valuation Compared to Its Peers
In this series, we’ll be looking at Ionis Pharmaceuticals’ (IONS) products and other factors that drive its revenues. This will give us a better understanding of what drives Ionis’s revenues.
How Vyvanse Could Fuel Shire’s ADHD Portfolio Sales
Vyvanse is Shire’s leading ADHD drug, constituting 80% of the company’s ADHD portfolio. In fiscal 2015, Vyvanse earned the company $1.7 billion.
How Does Incyte’s Valuation Compare to Peers?
Incyte, a Delaware-based biopharmaceutical company, is focused on developing and commercializing oncology products to cater to unmet medical needs.
Which Large-Cap Biotech Stock Fell the Most Last Week?
Large-cap biotech stocks struggled during the week ending March 18, 2016. The large-cap stocks within the iShares Nasdaq Biotechnology ETF (IBB) suffered the most, falling 3.9% during the week.
Alexion Pushes Down IBB’s Performance
Alexion Pharmaceuticals (ALXN) was the biggest loser among IBB’s large-cap stocks.
What’s Vertex’s Strategy to Sustain the Cystic Fibrosis Market?
Vertex Pharmaceuticals (VRTX) plans to continue to create high-value drugs for CF (cystic fibrosis). In 2015, CF product revenue stood at $983 million, a 110% increase in revenue.
Vertex Will Focus on Cystic Fibrosis Market in 2016
In July 2015, Vertex Pharmaceuticals’ (VRTX) Orkambi received FDA approval for cystic fibrosis. In November 2015, it received approval from the European Commission to treat CF.
Vertex’s Cystic Fibrosis Drugs and Their Controversial Prices
Vertex Pharmaceuticals priced Kalydeco at $294,000 per year and recently increased the price to $311,000. Vertex is not the only company pricing its drugs at the higher end.
Will Vertex Pharmaceuticals’ Valuation Multiple Improve?
These valuation multiples are susceptible to company- or industry-related material news. So any positive news results in a jump in the valuation multiple.
Orkambi: Recent Addition to the Vertex Portfolio
In July 2015, Vertex Pharmaceuticals’ (VRTX) Orkambi received FDA approval for treating cystic fibrosis in the United States for patients 12 years and older with two copies of the F508del mutation.
What Are Wall Street’s Estimates for Vertex Pharmaceuticals?
According to Wall Street analysts’ estimates, sales for Vertex Pharmaceuticals should be $408.8 million and $472.4 million for 4Q15 and 1Q16, respectively.
Vertex Pharmaceuticals: What Are Analysts’ Estimates?
Vertex Pharmaceuticals will report earnings for 4Q15 and fiscal 2015 on January 27, 2016. The company’s major focus area is hereditary disorder cystic fibrosis (or CF).
Vertex Up 3.2% as Healthcare Sector Continued to Lure Investors
XLV went up 1.2% on Tuesday, December 29. Its top stocks included Vertex Pharmaceuticals (VRTX), St Jude Medical (STJ), Cerner (CERN), and Biogen (BIIB).
Vertex Pharmaceuticals Brings up the Rear among XBI’s Large-Caps on December 3
Vertex Pharmaceuticals lost the most among the large-cap stocks on December 3, closing at $122.06—a decline of 6.4%.
Mylan Topped Large-Caps with New Launches, Share Repurchase Plan
Mylan (MYL) stock rose 6.4% for the week ended November 20, 2015. It went up on a couple of new drug launches and a share repurchase plan.
How Did the Biotechnology Subgroup of XLV Perform?
Among all the subgroups in the Health Care Select Sector SPDR ETF, the biotechnology subgroup came out ahead, returning 3% on November 18, 2015.
AbbVie Topped XBI’s Large-Cap Space
AbbVie (ABBV) rose 6.5% on November 2, 2015. The stock has continued its strong run and has now gained for seven consecutive trading sessions.
US Dollar Falls Sharply as Non-Farm Payroll Disappoints
The US Dollar Index fell sharply on the back of weak domestic labor data. It fell to 95.22 before regaining some strength towards the end of day.
Biotechnology Traded below Moving Averages in Last Week of August
Biotechnology and pharmaceuticals are the two largest subgroups of XLV. In the biotechnology subgroup, 100% of the stocks are trading below their 20-day, 50-day, and 100-day moving averages.
Key Risks Vertex Pharmaceuticals Faces
Biotechnology companies such as Regeneron, Alexion, Vertex, and Biogen have excessive business concentration risk, since they earn the majority of their revenues from a small number of drugs.
Illumina: Investor’s Overview of a Leading Biotechnology Company
An overview of Illumina, a leading biotechnology company, which holds a market capitalization of $27.5 billion.
Vertex Pharmaceuticals’ Cost Structure and EBITDA Margins
While mature biotechnology companies with drugs in multiple disease segments earn an average of 30%–40% EBITDA, margins of companies targeting only rare diseases can vary due to unique business models.
Vertex Has Strong Research and Development Pipeline
As part of its research and development, Vertex Pharmaceuticals (VRTX) has been actively exploring new cystic fibrosis (or CF) drugs as well as other indications for its existing drug Kalydeco.
Regeneron and Mylan End Up in Green for the Week
Among the top ten stocks in IBB for the week ending September 18, only Illumina, Regeneron, and Mylan ended positively.
Vertex Pharmaceuticals’ New Drug Orkambi Receives FDA Approval
On July 2, 2015, the FDA (U.S. Food and Drug Administration) approved Orkambi, a combination drug of lumacaftor and ivacaftor, for treating cystic fibrosis (or CF) patients.
Vertex Pharmaceuticals’ 3-Pronged Business Model
Vertex Pharmaceuticals’ (VRTX) business model includes revenues in three areas: products, royalties, and collaboration. There’s significant variability in royalty and collaboration revenues.
